Posted by Stephan Jacobs on Feb 17th, 2026
AtriCure (NASDAQ:ATRC) reported fourth-quarter and full-year 2025 results that management said reflected accelerating growth in several core franchises, improving profitability, and progress on major clinical and product development...
More of this article »